GSK Reports £8.4 Billion in Second-Quarter Sales
GlaxoSmithKline (GSK) announced its second-quarter financial results on July 28, reporting total sales of £8.4 billion. Specialty medicines were a key driver, generating £3.8 billion in sales, marking a 14% increase year-over-year. Vaccine sales also saw growth, reaching £2.3 billion, an 8% rise compared to the previous year. However, general medicines experienced a decline, with sales falling by 9% to £2.3 billion. The company's core operating profit for the quarter stood at £2.8 billion, and core earnings per share were 50.5 pence. Looking ahead, GSK has provided guidance for the full year 2026, projecting sales growth of 3% to 5%. Core operating profit is expected to increase by 7% to 9%, with core earnings per share also anticipated to grow by 7% to 9% over the same period.
GSK's second-quarter performance highlights a strategic shift, with specialty medicines and vaccines demonstrating robust growth, while general medicines face headwinds. This divergence suggests a successful reallocation of resources towards higher-margin, innovation-driven segments. The company's forward-looking guidance indicates confidence in sustained growth, likely underpinned by its R&D pipeline and market positioning in key therapeutic areas. Investors will monitor the sustainability of specialty medicine growth and the ability to stabilize or offset declines in the general medicines segment, considering the evolving healthcare landscape and competitive pressures.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.